Assessment of Blood Clotting and Bleeding Risks After Transcatheter Aortic Valve Replacement TAVR by Surgical Risk and Treatment Type

What this Trial Is About

Researchers are assessing the risks of blood clots ischemic events and bleeding after transcatheter aortic valve replacement TAVR in patients with severe aortic stenosis. This study focuses on how different antithrombotic therapies and surgical risk levels affect these risks. It also explores how the type of valve prosthesis and blood count factors like hemoglobin and platelets influence daily ischemic and bleeding risks over time. The aim is to improve personalized treatment strategies after TAVR. Participants will be grouped based on their surgical risk low, intermediate, or high and the antithrombotic therapy they receive, such as single or dual antiplatelet therapy, oral anticoagulation, or combinations. The study observes changes in antithrombotic treatments at 1 month, 90 days, and 1 year following TAVR. It also examines the impact of prosthesis characteristics and blood abnormalities on risk events using repeated-event analysis. During the study, participants ischemic and bleeding risks will be tracked at 30 days, 90 days, and 1 year after the procedure. Researchers will monitor therapy adjustments, the timing and type of changes, and collect data on anemia and low platelet counts. The study evaluates these outcomes to understand how risks fluctuate over time and how personalized antithrombotic strategies might better manage patients after TAVR.

Ischemic And Bleeding Risk Assessment After TAVR